Clinical Trials Browser

Bone Neoplasms, Breast Neoplasms, Glioma, Kidney Neoplasms, Lung Neoplasms, Lymphoma, Non-Hodgkin, Neoplasm Metastasis, Neoplasms, Hereditary Sensory and Autonomic Neuropathies, Pancreatic Neoplasms, Sarcoma, Colorectal Neoplasms, Leukemia-Lymphoma, Adult T-Cell

NCT06531447 2024-08-01

First-line Gemcitabine Plus Cisplatin in Locally Advanced (IIIC Stage) Breast Cancer Patients

Phase 2 Active not recruiting

200 enrolled

Breast

Fibrosis Of Extraocular Muscles, Congenital, 3A, with or without Extraocular Involvement, Breast Neoplasms

NCT02488967 2024-06-03

Doxorubicin Hydrochloride and Cyclophosphamide Followed by Paclitaxel With or Without Carboplatin in Treating Patients With Triple-Negative Breast Cancer

Phase 3 Active not recruiting

782 enrolled

Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT03595592 2024-03-06

APTneo

Phase 3 Active not recruiting

650 enrolled

Breast

Invasive Breast Cancer

NCT02641847 2024-01-25

TA(E)C-GP Versus A(E)C-T for the High Risk TNBC Patients and Validation of the mRNA-lncRNA Signature

Phase 2/3 Active not recruiting

503 enrolled

Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT04172259 2023-10-16

ACHP-THP vs EC-THP as Neoadjuvant Therapy for HER2-positive EBC

Phase 2 Active not recruiting

156 enrolled

Breast

Breast Neoplasms

NCT01057069 2022-10-12

neo-TN

Phase 2/3 Active not recruiting

310 enrolled

Breast

Breast Neoplasms

Clinical Trials

CARABELA

Doxorubicin Hydrochloride, Cyclophosphamide, and Paclitaxel With or Without Bevacizumab in Treating Patients With Lymph Node-Positive or High-Risk, Lymph Node-Negative Breast Cancer

Trastuzumab Deruxtecan (T-DXd) Alone or in Sequence With THP, Versus Standard Treatment (ddAC-THP), in HER2-positive Early Breast Cancer

Study Of Ruxolitinib (INCB018424) With Preoperative Chemotherapy For Triple Negative Inflammatory Breast Cancer

Neoadjuvant Pyrotinib in HR-positive and HER2-low High-risk Early Breast Cancer

A Phase III Randomised Study to Evaluate Dato-DXd and Durvalumab for Neoadjuvant/Adjuvant Treatment of Triple-Negative or Hormone Receptor-low/HER2-negative Breast Cancer

A Phase 2 Study of Eribulin Followed by AC as Preoperative Therapy for HER2-negative Inflammatory Breast Cancer

Paclitaxel & Cyclophosphamide With or Without Trastuzumab Before Surgery in Treating Previously Untreated Breast Cancer

CemiHALT

Neoadjuvant Pembrolizumab + Decitabine Followed by Std Neoadj Chemo for Locally Advanced HER2- Breast Ca

S0221 Adjuvant Doxorubicin, Cyclophosphamide, and Paclitaxel in Treating Patients With Breast Cancer

A Phase Ib Safety lead-in, Followed by Phase II Trial of ADG106 in Combination With Neoadjuvant Chemotherapy in HER2 Negative Breast Cancer

KEYNOTE-756

Phase 2 Trial of Neoadjuvant Weekly Carboplatin Plus Paclitaxel in Triple Negative Breast Cancer

BARBICAN

SAFIR02_Breast

9-ING-41 in Patients with Advanced Cancers

First-line Gemcitabine Plus Cisplatin in Locally Advanced (IIIC Stage) Breast Cancer Patients

Doxorubicin Hydrochloride and Cyclophosphamide Followed by Paclitaxel With or Without Carboplatin in Treating Patients With Triple-Negative Breast Cancer

APTneo

TA(E)C-GP Versus A(E)C-T for the High Risk TNBC Patients and Validation of the mRNA-lncRNA Signature

ACHP-THP vs EC-THP as Neoadjuvant Therapy for HER2-positive EBC

neo-TN